Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China
· Delayed Price · Currency is CNY 27.85
+0.24 (0.87%)
Apr 29, 2026, 3:04 PM CST
SHE:300204 Revenue
Staidson (Beijing) BioPharmaceuticals had revenue of 46.90M CNY in the quarter ending March 31, 2026, a decrease of -25.81%. This brings the company's revenue in the last twelve months to 203.92M, down -30.42% year-over-year. In the year 2025, Staidson (Beijing) BioPharmaceuticals had annual revenue of 220.23M, down -32.20%.
Revenue (ttm)
203.92M
Revenue Growth
-30.42%
P/S Ratio
65.25
Revenue / Employee
414.46K
Employees
484
Market Cap
13.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 220.23M | -104.58M | -32.20% |
| Dec 31, 2024 | 324.82M | -39.36M | -10.81% |
| Dec 31, 2023 | 364.18M | -184.81M | -33.66% |
| Jan 1, 2023 | 548.99M | -35.30M | -6.04% |
| Dec 31, 2021 | 584.29M | 159.08M | 37.41% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| InventisBio | 37.29M |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |
| Chengzhi | 10.87B |
| Mabwell (Shanghai) Bioscience | 662.52M |
| Anhui Anke Biotechnology (Group) | 2.56B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Jinyu Bio-technology | 1.33B |